Breaking News

Top Picks 2019- Sangamo Therapeutics SGMO

Stock MarketsJan 11, 2019 07:15AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters.

Sangamo Therapeutics (SGMO) is the leader in gene editing, and an unappreciated leader in gene therapy as well; with many value drivers coming in 2019, the stock is our top speculative pick for the coming year, explains Jay Silverman, analyst with The Medical Technology Stock Letter.

The company has more in vivo gene editing studies underway than the entire gene editing universe combined, including the CRSPR companies.

A year ago in the first in vivo gene editing study in history, SGMO began treating adults with MPSII with SB-913. Management has always noted that once safety and efficacy was shown in the initial adult participants, it would discuss the results with the FDA and Safety Monitoring Committee (SMC) in order to allow younger patients to be given the novel gene editing treatment.

On the Q3:18 quarterly call, the company announced that adolescents aged 12-17 would begin to be enrolled. Less than 3 weeks later, SGMO has posted an update saying that children as young as 5 year olds are now being enrolled.

This is a clear signal that the regulators are in agreement on the company’s program, as permanently editing the genes of a child has potential risks involved — and the agency believes that the initial responses warrant taking such risks.

Moreover, if gene editing occurs at an early age, many of the neurological and physical symptoms of MPSII could be stopped well before the condition advances.

The clean safety of SGMO’s ZFN technology stands alone in the revolutionary world of gene editing, especially compared with potential off-target toxicities of other technologies (e.g., CRSPR, etc.).

When SGMO announced initial positive results in August, the stock dropped sharply because while delivering significant drops in GAG, they could not measure IDS levels with the available assay used at the time.

Since, then the company has been working on developing a new test to measure IDS levels that appear to be gobbled up by organs (e.g., liver) as soon as they are produced. Measurable IDS enzyme levels appear to be the gating factor in gaining the Street’s appreciation of this revolutionary and positive study.

In 2019, SGMO will emerge as the leader in gene editing as positive clinical data will validate both the platform and management’s ability to execute. In addition to clinical catalysts, there is strong potential for more collaborations (e.g., CNS/Immunology).

The stock is a favorite of ours for 2019 as either on its own and/or compared with other gene editing stocks, in our view, Sangamo is undervalued. The stock is a buy under $30 with a target price of $40.

Subscribe to The Medical Technology Stock Letter here…

Top Picks 2019- Sangamo Therapeutics SGMO

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email